PAI
Palo Alto Investors Portfolio holdings
AUM
$470M
This Quarter Return
+23.45%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$863M
AUM Growth
+$863M
(-2.7%)
Cap. Flow
-$142M
Cap. Flow
% of AUM
-16.47%
Top 10 Holdings %
Top 10 Hldgs %
80.4%
Holding
40
New
2
Increased
10
Reduced
8
Closed
1
Top Buys
| 1 |
ELEV
Elevation Oncology
ELEV
|
$1.22M |
| 2 |
Generation Bio
GBIO
|
$424K |
| 3 |
STAAR Surgical
STAA
|
$96.6K |
| 4 |
AnaptysBio
ANAB
|
$93.6K |
| 5 |
BLUE
bluebird bio
BLUE
|
$72K |
Top Sells
| 1 |
Insmed
INSM
|
$153M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$27.3M |
| 3 |
Amicus Therapeutics
FOLD
|
$3.12M |
| 4 |
Align Technology
ALGN
|
$2.74M |
| 5 |
eHealth
EHTH
|
$1.66M |
Sector Composition
| 1 | Healthcare | 93.61% |
| 2 | Financials | 1.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$28.8B
| $143M | 16.61% | 2,138,963 -2,284,406 | -52% | -$153M |
|
2
BioMarin Pharmaceuticals
BMRN
$11.2B
| $93M | 10.78% | 1,130,167 -4,402 | -0.4% | -$362K |
|
|
3
Amicus Therapeutics
FOLD
$2.34B
| $89.6M | 10.38% | 9,029,843 -314,259 | -3% | -$3.12M |
|
4
United Therapeutics
UTHR
$13.8B
| $85M | 9.85% | 266,914 -845 | -0.3% | -$269K |
|
5
Biogen
BIIB
$19.4B
| $67M | 7.76% | 289,050 -908 | -0.3% | -$210K |
|
|
6
STAAR Surgical
STAA
$1.36B
| $65.8M | 7.62% | 1,381,619 +2,029 | +0.1% | +$96.6K |
|
7
Acadia Pharmaceuticals
ACAD
$4.38B
| $39.3M | 4.55% | 2,418,841 +3,898 | +0.2% | +$63.3K |
|
8
Prothena Corp
PRTA
$441M
| $34.4M | 3.99% | 1,666,378 +2,930 | +0.2% | +$60.5K |
|
9
Sarepta Therapeutics
SRPT
$1.78B
| $31.9M | 3.69% | 201,683 +418 | +0.2% | +$66K |
|
|
10
AnaptysBio
ANAB
$569M
| $20.1M | 2.33% | 803,641 +3,735 | +0.5% | +$93.6K |
|
11
Iovance Biotherapeutics
IOVA
$807M
| $17M | 1.97% | 2,116,403 +3,592 | +0.2% | +$28.8K |
|
|
RVNC
12
DELISTED
Revance Therapeutics, Inc.
RVNC
| $13.5M | 1.57% | 5,257,086 +9,082 | +0.2% | +$23.3K |
|
13
Alkermes
ALKS
$4.78B
| $11.9M | 1.38% | 495,592 | – | – |
|
|
SAGE
14
DELISTED
Sage Therapeutics
SAGE
| $11M | 1.27% | 1,010,833 +5,057 | +0.5% | +$54.9K |
|
|
15
eHealth
EHTH
$118M
| $10.6M | 1.23% | 2,350,190 -365,491 | -13% | -$1.66M |
|
16
NovoCure
NVCR
$1.38B
| $9.63M | 1.12% | 561,908 | – | – |
|
|
17
Align Technology
ALGN
$10.3B
| $9.12M | 1.06% | 37,772 -11,333 | -23% | -$2.74M |
|
18
Syndax Pharmaceuticals
SNDX
$1.41B
| $8.32M | 0.96% | 405,193 | – | – |
|
|
SLRN
19
DELISTED
ACELYRIN
SLRN
| $7.56M | 0.88% | 1,715,180 | – | – |
|
|
NVRO
20
DELISTED
NEVRO CORP.
NVRO
| $6.32M | 0.73% | 750,371 | – | – |
|
21
Cytokinetics
CYTK
$4.23B
| $6.05M | 0.7% | 111,717 | – | – |
|
22
Gossamer Bio
GOSS
$562M
| $5.66M | 0.66% | 6,277,093 -114,682 | -2% | -$103K |
|
|
ELEV
23
DELISTED
Elevation Oncology
ELEV
| $4.86M | 0.56% | 1,800,106 +453,440 | +34% | +$1.22M |
|
|
BLUE
24
DELISTED
bluebird bio
BLUE
| $4.56M | 0.53% | 4,633,351 +73,180 | +2% | +$72K |
|
25
Karyopharm Therapeutics
KPTI
$61.7M
| $4.43M | 0.51% | 5,102,193 | – | – |
|